Evaluating treatment recommendations for children with Burkitt's Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This study is trying to find better ways to diagnose and treat children with Burkitt's Lymphoma in Sub-Saharan Africa to improve their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | French Africa Pediatric Oncology Group Academic / other |
| Drugs / interventions | rituximab |
| Locations | 7 sites (Ouagadougou and 6 other locations) |
| Trial ID | NCT04425421 on ClinicalTrials.gov |
What this trial studies
This observational study, led by the French African Pediatric Oncology Group, aims to improve the early diagnosis and treatment response evaluation for children with Burkitt's Lymphoma across at least 14 Sub-Saharan countries. It focuses on children with stage I and II disease, allowing for timely treatment adjustments, and seeks to intensify treatment for those with stage IV disease. By gathering data on treatment outcomes, the study hopes to enhance the overall management of this aggressive cancer in pediatric patients.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with Burkitt's Lymphoma, particularly those in stages I, II, or IV.
Not a fit: Patients who have previously received treatment for Burkitt's Lymphoma or have other illnesses that complicate treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and outcomes for children diagnosed with Burkitt's Lymphoma.
How similar studies have performed: Previous studies focusing on Burkitt's Lymphoma treatment have shown promise, but this specific approach of early evaluation and treatment adjustment is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment. \- Exclusion Criteria: Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
Where this trial is running
Ouagadougou and 6 other locations
- Hopital Yalgado Ouedraogo — Ouagadougou, Burkina Faso (Recruiting)
- CHU de Treichville à ABIDJAN — Abidjan, Côte d’Ivoire (Recruiting)
- Cliniques Universitaires de Kinshasa — Kinshasa, Kinshasa City, Democratic Republic of the Congo (Recruiting)
- Cliniques Universitaires de Lubumbashi (CUL) — Lubumbashi, Democratic Republic of the Congo (Recruiting)
- HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona — Antananarivo, Madagascar (Recruiting)
- CHU Gabriel Touré (HGT) — Bamako, Mali (Recruiting)
- Hôpital Aristide Le Dantec — Dakar, Senegal (Recruiting)
Study contacts
- Study coordinator: Chantal Ms BOUDA, Dr.
- Email: cgbouda@yahoo.fr
- Phone: 00(226)70 10 01 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.